Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptotagmin-like protein 3 (SYTL3)
- Target
- SYTL3
- Molecular classification
- Other (C2 domain–containing peripheral membrane protein; Rab effector)
01
Overview
Synaptotagmin-like protein 3 (SYTL3) is a member of the synaptotagmin-like protein family and acts as an effector for the small GTPase Rab27A, playing a critical role in vesicular and membrane trafficking. It binds phospholipids in the presence of calcium ions through its C2 domain, and is involved in processes such as granule exocytosis and regulated secretion—particularly facilitating peripheral melanosome distribution in melanocytes. SYTL3 also has regulatory functions in the developing cortex, where it influences neuronal migration and neurotransmitter release. Mutations or deregulation in genes of this pathway (including Rab effectors) have been linked to diseases such as Griscelli syndrome and certain cancers, but SYTL3 itself is not currently recognized as a therapeutic target or as the primary cause of any specific human disease[1][2][3][6].
- Other names
- SLP3Exophilin-6SYTL3phSYTL3Q4VX76
02
Biological functions
Vesicular traffickingMembrane traffickingCalcium-dependent phospholipid bindingRegulation of cortical neuronal migrationModulation of neurotransmitter release
03
Disease associations
Neurodevelopmental disorderCancer (specifically, deregulation in bladder cancer and association with Griscelli syndrome in the context of related Rab effectors)
Beyond the preview
Go deeper on Synaptotagmin-like protein 3 (SYTL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synaptotagmin-like protein 3 (SYTL3).